Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T
The billionaire-backed Parker Institute for Cancer Immunotherapy is investing and partnering with a biotech their researchers believe has the potential to develop a new-model CAR-T that can be better guided down narrow pathways and equipped with a convenient on/off switch to help avoid any fatal accidents.
Parker CEO Jeffrey Bluestone isn’t giving away any numbers right now, but he says the institute’s equity investment in Xyphos Biosciences “isn’t trivial.” The primary purpose of the investment — and the research alliance that plugs Xyphos into their network of prominent investigators — is to accelerate the work and prevent it from getting stuck in the R&D mud.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.